
|Videos|February 27, 2017
Medicare Part D and Oncology
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Advertisement
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Common Virus May Hold New Clues to Lupus
2
SHR-A1811 Plus Pertuzumab Improves Survival in HER2-Positive Metastatic Breast Cancer
3
Zongertinib Shows Clinically Meaningful Efficacy in Advanced HER2-Mutant NSCLC
4
When to Call, When to Counsel: Statin Drug Interactions
5

















































































































































































































